Exicure, INC 8-K filings

Exicure, Inc. announces director resignation, board expansion, new director appointments, and the formation of a Compensation Committee, effective June 30, 2026.

Exicure, Inc. announced it received a Nasdaq delinquency notice for a delayed 10-Q filing due to personnel changes, but has since filed the report and believes it has regained compliance.

Exicure, Inc. announces the appointment of Yoontae Han as a director and Young Seung Ko as Chief Operating Officer, alongside a change in Audit Committee Chair.

Exicure has reached a settlement in consolidated stockholder derivative litigation involving corporate governance reforms.

Exicure, Inc. announced the resignation of Sangjin Yeo from its Board of Directors and Audit Committee, effective March 27, 2026, citing no disagreements.

Exicure, Inc. announced its full year 2025 financial results, revealing a significant decrease in cash and a going concern warning despite a reduced net loss driven by a one-time gain.

Exicure, Inc. announced significant changes to its Board of Directors and executive leadership, including the resignation of its CEO and CFO, effective February 9, 2026.

Exicure, Inc. announced the achievement of a key Phase 2 clinical trial milestone for its novel stem cell mobilizer, triggering a $1 million payment to GPCR Therapeutics Inc.

Exicure, Inc. has redeemed $3.125 million in intercompany convertible bonds, simplifying its internal capital structure and enhancing liquidity for its biotechnology operations.

Exicure, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of two Class II directors, ratification of its independent auditor, and advisory approval of executive compensation.

Exicure, Inc. announced its third-quarter 2025 financial results, reporting a significant net loss increase and a going concern warning due to insufficient cash to fund operations.

Exicure, Inc. announced significant changes to its Board of Directors, including the appointment of two new members and the resignation of four, alongside a new Audit Committee Chairman.

Exicure, Inc. reported a significant increase in net loss for Q2 2025 and disclosed a going concern warning, citing insufficient cash to fund operations.

Exicure, Inc. announced it has regained compliance with Nasdaq's periodic filing requirements, resolving a previous listing deficiency.

Exicure, Inc. reported a net income of $3.0 million for Q1 2025, primarily due to a $6 million gain from early lease termination, but disclosed insufficient cash to fund operations and an urgent need for substantial additional financing.

Exicure, Inc. has announced significant adjustments to the annual base salaries and severance terms for its Chief Executive Officer, Andy Yoo, and Chief Financial Officer, Seung Ik Baik, effective April 1, 2025.

Exicure, Inc. announced it received a delinquency notification from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Exicure's South Korean subsidiary, KC Creation, entered into a convertible bond agreement to raise approximately $3.125 million for future stock acquisitions.

Exicure, Inc. announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs, effective April 10, 2025.

Exicure, Inc. reports its full year 2024 financial results, highlighting a reduced net loss and ongoing exploration of strategic alternatives after ceasing R&D activities.

Exicure, Inc. reports the resignation of Jiyoung Hwang and Paul Kang from its Board of Directors, with Paul Kang transitioning to a consulting role.

Exicure, Inc. secures $2 million in gross proceeds through a common stock purchase agreement with Shin Chang Partners and RMS0718 Co., Ltd., while also terminating its Chicago office lease for a $6 million gain.

Exicure, Inc. has acquired GPCR Therapeutics USA and entered into a license agreement to further develop and commercialize GPCR's technologies, including a promising Phase 2 clinical trial for blood cancer.

Exicure Inc. has acquired GPCR Therapeutics USA and entered into a licensing agreement to further develop and commercialize GPCR technologies.

Exicure, Inc. has appointed Chang Keun Choi and Minwoo Kang to its Audit Committee, with Mr. Kang as Chair, and received $8.7 million from HiTron Systems Inc.

Exicure Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, avoiding potential delisting.

Exicure, Inc. announces the approval of an $8.7 million equity financing from HiTron Systems Inc., along with executive management and board changes following a change of control transaction.

Exicure, Inc. secures $8.7 million in additional funding from HiTron Systems Inc., alongside a major restructuring of its board and executive leadership.

Exicure Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement following a series of stock sales, increasing its equity to approximately $4.3 million.

Exicure, Inc. has entered into a definitive agreement to sell 433,332 shares of its common stock to SangSangIn Investment & Securities Co., Ltd. for approximately $2 million.